At the recent annual meeting of America’s Health Insurance Plans (AHIP), Harvard Pilgrim was recognized as one plan leading the charge toward outcomes-based contracting with pharmaceutical companies.

This new approach is designed to help control escalating drug prices while putting the focus on positive medical outcomes for patients. Harvard Pilgrim CEO Eric Schultz and Eli Lilly CEO David Ricks shared the stage in a panel focused on this collaborative way to balance innovation and affordability in pharmaceuticals.

Read related articles in Modern Healthcare and Fierce Healthcare.